Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 2 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Lancet Oncol. 2022 Jul;23(7):851-864. doi: 10.1016/S1470-2045(22)00284-4. Epub 2022 Jun 4.
Lancet Oncol. 2022.
PMID: 35671774
Free PMC article.
Clinical Trial.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ.
Jones RH, et al. Among authors: carucci m.
Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5.
Lancet Oncol. 2020.
PMID: 32035020
Free PMC article.
Clinical Trial.
Item in Clipboard
Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.
Jones RH, Casbard A, Carucci M, Foxley A, Howell SJ.
Jones RH, et al. Among authors: carucci m.
Lancet Oncol. 2020 May;21(5):e234. doi: 10.1016/S1470-2045(20)30237-0.
Lancet Oncol. 2020.
PMID: 32359499
No abstract available.
Item in Clipboard
Cite
Cite